Benefits and Limitations of TKIs in Patients with Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis
Conclusion: Treatment with TKIs in MTC patients with progressive disease is associated with a moderate therapeutic benefit, with achievement of either disease stability or partial response in 73%. The toxicity of these drugs is not negligible, but it is, nonetheless, manageable.Eur Thyroid J
Source: European Thyroid Journal - Category: Endocrinology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Endocrinology | Study | Thyroid | Thyroid Cancer | Toxicology